text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

请选择数量

CAS RN: 170787-99-2 | 產品號碼: E1356

Efaproxiral Sodium


纯度/分析方法: >98.0%(T)(HPLC)
別名
  • RSR 13 Sodium
  • Sodium 2-[4-[2-[(3,5-Dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoate
  • 2-[4-[2-[(3,5-Dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic Acid Sodium Salt
文檔:
250MG
$133.00
9   18  

*以上價格僅為出廠價不含運費關稅等,詳情請與 當地經銷商TCI 洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準,敬請留意。


產品號碼 E1356
純度/分析方法 >98.0%(T)(HPLC)
分子式 / 分子量 C__2__0H__2__2NNaO__4 = 363.39  
外觀與形狀(20°C) Solid
儲存條件 -20°C
儲存在惰性氣體下 Store under inert gas
應避免的情況 Hygroscopic
CAS RN 170787-99-2
Reaxys-RN 8959239
MDL編號

MFCD02093864

質量規格
Appearance White to Almost white powder to lump
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 98.0 %(calcd.on anh.substance)
Melting point 240.0 to 244.0 °C
Water max. 13.0 %
性質
GHS
相關法規
物流信息
HS編碼* 2924.29-000
*此H.S.編碼用於日本出口報關, 不適用於您所在國家或地區的進口申報
Application
Efaproxiral Sodium: Developed as an Allosteric Modifier of Hemoglobin and a Radiation Sensitizer

Efaproxiral sodium (RSR 13 sodium), an analogue of the antilipemic agent bezafibrate [B3346], was developed as an allosteric modifier of hemoglobin1,2) and a radiation sensitizer.3) In the 2000s, efaproxiral sodium was tested in a clinical trial to increase the efficacy of certain chemotherapy agents which have reduced efficacy against hypoxic tumors, and can thus be made more effective by increased offloading of oxygen from hemoglobin-bound oxygen into the tumor tissues.4) But the clinical trial was dropped out in Phase III trials. In 2009, Efaproxiral was added to the World Anti-Doping Agency (WADA) list of Prohibited Substances as an artificially enhancer of the uptake, transport or delivery of oxygen.5) (The product is for research purpose only.)

References


文件
SDS搜索
請選擇語言。

請求的SDS不可用。

• 請確認您輸入的產品編碼。

• 如果您輸入的信息無誤,  請 聯繫我們

檢驗報告(CoA)及其他文檔
請輸入批號 輸入的批號不正確
其他文件